Terumo Corporation (TRUMY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Terumo Corporation (TRUMY) with AI Score 51/100 (Hold). Terumo Corporation is a global medical device company specializing in the manufacture and sale of a wide range of medical products and equipment. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Terumo Corporation (TRUMY) Healthcare & Pipeline Overview
Terumo Corporation, a Japanese medical device manufacturer, develops, produces, and distributes a diverse portfolio of medical products and equipment across three segments, including cardiac and vascular, medical care solutions, and blood and cell technologies, serving a global healthcare market with a focus on innovation and quality.
Investment Thesis
Terumo Corporation presents a compelling investment case based on its diversified product portfolio, global presence, and consistent profitability. With a market capitalization of $19.03 billion and a P/E ratio of 23.89, Terumo demonstrates financial stability. The company's 11.7% profit margin and 53.3% gross margin indicate efficient operations. Growth catalysts include expanding its presence in emerging markets and continuous innovation in its core product segments. Potential risks include regulatory changes in the medical device industry and increased competition from established players and new entrants. The company's beta of 0.25 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $19.03 billion, reflecting its significant presence in the medical device industry.
- P/E ratio of 23.89, indicating investor confidence in its earnings potential.
- Profit margin of 11.7%, showcasing efficient operations and profitability.
- Gross margin of 53.3%, highlighting the company's ability to maintain strong pricing power.
- Dividend yield of 1.35%, providing a steady income stream for investors.
Competitors & Peers
Strengths
- Diversified product portfolio
- Global presence and distribution network
- Strong brand reputation
- Consistent profitability
Weaknesses
- Exposure to currency fluctuations
- Dependence on regulatory approvals
- Limited presence in certain emerging markets
- Potential for product recalls
Catalysts
- Continued innovation in cardiac and vascular devices, leading to new product launches and market share gains.
- Expansion in emerging markets, driving revenue growth and increasing global presence.
- Potential strategic acquisitions to expand product portfolio and geographic reach.
- Growth in contract manufacturing services for pharmaceutical companies, providing a stable revenue stream.
Risks
- Increased competition from established players and new entrants in the medical device industry.
- Regulatory changes in the medical device industry, impacting product approvals and market access.
- Exposure to currency fluctuations, affecting financial results and profitability.
- Product liability claims and recalls, potentially damaging brand reputation and financial performance.
Growth Opportunities
- Expansion in Emerging Markets: Terumo has the opportunity to expand its presence in emerging markets, such as China and India, where healthcare spending is rapidly increasing. These markets offer significant growth potential for Terumo's products, particularly in the cardiac and vascular and medical care solutions segments. The rising prevalence of chronic diseases and increasing access to healthcare in these regions are expected to drive demand for Terumo's medical devices and equipment. Timeline: Ongoing.
- Innovation in Cardiac and Vascular Devices: Terumo can continue to invest in research and development to develop innovative cardiac and vascular devices, such as drug-eluting stents and advanced imaging catheters. These products can address unmet clinical needs and improve patient outcomes, driving revenue growth and market share gains. The global market for cardiac and vascular devices is expected to grow at a steady pace, driven by the increasing prevalence of cardiovascular diseases. Timeline: Ongoing.
- Growth in Blood and Cell Technologies: Terumo can capitalize on the growing demand for blood and cell technologies, such as blood bags, component collection systems, and cell expansion systems. These products are essential for blood banks, hospitals, and research institutions. The increasing demand for blood transfusions and cell therapies is expected to drive growth in this segment. Timeline: Ongoing.
- Strategic Acquisitions: Terumo can pursue strategic acquisitions to expand its product portfolio, geographic reach, and technological capabilities. Acquisitions can provide access to new markets, technologies, and customer segments, accelerating growth and enhancing competitiveness. The medical device industry is characterized by consolidation, and Terumo can leverage acquisitions to strengthen its position in the market. Timeline: Ongoing.
- Contract Manufacturing for Pharmaceutical Companies: Terumo can expand its contract manufacturing services for pharmaceutical companies, providing prefilled syringes, devices for drug kits, and other products. This business offers a stable revenue stream and leverages Terumo's manufacturing expertise and infrastructure. The increasing demand for prefilled syringes and drug delivery devices is expected to drive growth in this segment. Timeline: Ongoing.
Opportunities
- Expansion in emerging markets
- Development of innovative products
- Strategic acquisitions
- Growth in contract manufacturing
Threats
- Increased competition
- Regulatory changes
- Economic downturns
- Product liability claims
Competitive Advantages
- Strong brand reputation for quality and reliability.
- Diversified product portfolio across multiple medical specialties.
- Global presence with established distribution networks.
- Continuous innovation and investment in research and development.
About TRUMY
Terumo Corporation, founded in 1921 as Sekisen Ken-onki Corporation, initially focused on manufacturing clinical thermometers. Over the decades, Terumo expanded its product line and global presence, becoming a leading manufacturer of medical devices and equipment. In October 1974, the company officially changed its name to Terumo Corporation. Today, Terumo operates through three primary segments: Cardiac and Vascular Company, which offers products such as angiographic guidewires, catheters, and stents; Medical Care Solutions Company, providing syringes, infusion pumps, and I.V. solutions; and Blood and Cell Technologies Company, which focuses on blood bags, collection systems, and cell expansion systems. Terumo's products are used in a wide range of medical settings, from hospitals and clinics to home healthcare. With its headquarters in Tokyo, Japan, Terumo has a global reach, serving customers in numerous countries and regions. The company is committed to innovation and quality, continuously developing new and improved medical technologies to meet the evolving needs of healthcare professionals and patients worldwide.
What They Do
- Manufactures and sells angiographic guidewires and catheters.
- Produces vascular closure devices and PTCA balloon catheters.
- Develops and distributes coronary and peripheral stents.
- Offers intravascular ultrasound systems and imaging catheters.
- Provides oxygenators and cardio-pulmonary bypass systems.
- Manufactures syringes, infusion pumps, and I.V. solutions.
- Offers blood glucose monitoring systems and blood pressure monitors.
- Develops blood bags and component collection systems.
Business Model
- Develops and manufactures a wide range of medical devices and equipment.
- Sells products through direct sales, distributors, and partnerships.
- Generates revenue from three main segments: Cardiac and Vascular, Medical Care Solutions, and Blood and Cell Technologies.
- Invests in research and development to innovate new products and improve existing ones.
Industry Context
Terumo Corporation operates in the global medical device industry, which is characterized by continuous innovation, increasing regulatory scrutiny, and growing demand for advanced healthcare solutions. The industry is driven by factors such as an aging population, rising prevalence of chronic diseases, and technological advancements. Terumo competes with other major players in the medical device market, including CLPBF, CLPBY, KONEF, OCPNF, and OTSKF. The company's diversified product portfolio and global presence provide a competitive edge in this dynamic and competitive landscape.
Key Customers
- Hospitals and clinics
- Blood banks and transfusion centers
- Research institutions
- Pharmaceutical companies
- Home healthcare providers
TRUMY Financials
TRUMY Price Today & Live Chart
Terumo Corporation (TRUMY) stock price: Price data unavailable
TRUMY Latest News
-
Arterial Device-Focused Inari Medical Likely Acquisition Target, Shares Are Attractively Valued: Analyst
benzinga · Jan 23, 2024
-
Pfizer/BioNTech COVID-19 Jab Neutralizes Virus Variant In Brazil: Reuters
· Mar 9, 2021
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Highs On Tuesday
· Feb 11, 2020
TRUMY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TRUMY.
Price Targets
Wall Street price target analysis for TRUMY.
TRUMY MoonshotScore
What does this score mean?
The MoonshotScore rates TRUMY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Arterial Device-Focused Inari Medical Likely Acquisition Target, Shares Are Attractively Valued: Analyst
Pfizer/BioNTech COVID-19 Jab Neutralizes Virus Variant In Brazil: Reuters
Stocks That Hit 52-Week Lows On Tuesday
Stocks That Hit 52-Week Highs On Tuesday
Leadership: Hikaru Samejima
Managing Director
Hikaru Samejima serves as a Managing Director at Terumo Corporation, overseeing a global workforce of over 30,000 employees. Information regarding his specific educational background and prior roles is not available in the provided data. As a key leader within Terumo, Samejima plays a crucial role in shaping the company's strategic direction and driving its growth initiatives in the competitive medical device industry.
Track Record: Specific achievements and milestones under Hikaru Samejima's leadership are not detailed in the provided data. However, as a Managing Director, he is responsible for guiding Terumo's overall performance, including its financial results, product innovation, and market expansion efforts. His leadership is essential for maintaining Terumo's position as a leading global medical device manufacturer.
Terumo Corporation ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. TRUMY, as an ADR, allows U.S. investors to invest in Terumo Corporation without the complexities of cross-border transactions. Each TRUMY ADR represents a specific number of Terumo Corporation's shares traded on its home market.
- Home Market Ticker: Tokyo Stock Exchange, Japan
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: TRUM
TRUMY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies trading on this tier typically have limited or no financial disclosure requirements, making it difficult for investors to assess their financial health and performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to stringent listing standards or regulatory oversight, which increases the risk for investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Low trading volume and liquidity
- Potential for price manipulation
- Lack of regulatory oversight
- Higher risk of fraud or scams
- Verify the company's registration and legal status.
- Research the company's management team and their track record.
- Attempt to obtain audited financial statements, if available.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Be wary of unsolicited investment offers or promotions.
- Established history as Terumo Corporation
- Global presence and operations
- Presence in the medical device industry
- ADR status, indicating some level of regulatory compliance
Terumo Corporation Healthcare Stock: Key Questions Answered
What does Terumo Corporation do?
Terumo Corporation is a global medical device company that develops, manufactures, and distributes a wide range of medical products and equipment. Its three main segments are Cardiac and Vascular, which offers products like catheters and stents; Medical Care Solutions, providing syringes and infusion pumps; and Blood and Cell Technologies, focusing on blood bags and cell expansion systems. Terumo serves hospitals, clinics, blood banks, and pharmaceutical companies worldwide, contributing to various aspects of healthcare.
What do analysts say about TRUMY stock?
AI analysis is pending for TRUMY. Generally, analysts consider factors such as Terumo's financial performance, growth prospects, and competitive positioning when evaluating the stock. Key valuation metrics include the P/E ratio of 23.89 and the dividend yield of 1.35%. Growth considerations include the company's expansion in emerging markets and its innovation in medical devices. Investors should conduct their own research and consult with a financial advisor before making any investment decisions.
What are the main risks for TRUMY?
The main risks for TRUMY include increased competition in the medical device industry, regulatory changes impacting product approvals, and exposure to currency fluctuations. Product liability claims and recalls can also pose a risk to the company's brand reputation and financial performance. Additionally, investing in TRUMY through the OTC market carries additional risks due to limited financial disclosure and lower liquidity.
What are the key factors to evaluate for TRUMY?
Terumo Corporation (TRUMY) currently holds an AI score of 51/100, indicating moderate score. Key strength: Diversified product portfolio. Primary risk to monitor: Increased competition from established players and new entrants in the medical device industry. This is not financial advice.
How frequently does TRUMY data refresh on this page?
TRUMY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven TRUMY's recent stock price performance?
Recent price movement in Terumo Corporation (TRUMY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diversified product portfolio. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider TRUMY overvalued or undervalued right now?
Determining whether Terumo Corporation (TRUMY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying TRUMY?
Before investing in Terumo Corporation (TRUMY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide further insights.